Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
All stages of prostate cancer without bone metastases
No evidence of severe osteoporosis
ECOG performance status 0, 1 or 2
You may not be if
Surgery / fracture at the lumbosacral spine, bilateral hip implants
Evidence of metabolic bone diseases,
Treatment with bisphosphonates or calcitonin within the previous year or chronic systemic corticosteroid treatment
Abnormal kidney or liver function
Other cancers within the last 5 years
Clareo Health | Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy
